GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » Margin of Safety % (DCF FCF Based)

HALO (Halozyme Therapeutics) Margin of Safety % (DCF FCF Based) : N/A (As of Dec. 13, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Halozyme Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.


Competitive Comparison of Halozyme Therapeutics's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Halozyme Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Margin of Safety % (DCF FCF Based) falls into.



Halozyme Therapeutics Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Halozyme Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Executives
Michael J. Labarre officer: SVP, Chief Technical Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley director, officer: President and CEO C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Nicole Labrosse officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Akiko Moni Miyashita director 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley director 1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey officer: SVP, Chief Commerical Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121